Dyne Therapeutics, Inc. $DYN Shares Bought by Rafferty Asset Management LLC

Rafferty Asset Management LLC boosted its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 93.4% during the 3rd quarter, Holdings Channel.com reports. The firm owned 213,211 shares of the company’s stock after purchasing an additional 102,963 shares during the quarter. Rafferty Asset Management LLC’s holdings in Dyne Therapeutics were worth $2,697,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of DYN. Aberdeen Group plc boosted its stake in shares of Dyne Therapeutics by 15.0% in the third quarter. Aberdeen Group plc now owns 556,733 shares of the company’s stock worth $7,043,000 after buying an additional 72,770 shares during the last quarter. Saturn V Capital Management LP acquired a new position in Dyne Therapeutics in the second quarter valued at approximately $13,856,000. Arcadia Investment Management Corp MI boosted its position in Dyne Therapeutics by 23.1% in the 2nd quarter. Arcadia Investment Management Corp MI now owns 55,215 shares of the company’s stock worth $526,000 after purchasing an additional 10,350 shares in the last quarter. Bryce Point Capital LLC purchased a new stake in Dyne Therapeutics in the 2nd quarter worth approximately $115,000. Finally, Squarepoint Ops LLC grew its stake in shares of Dyne Therapeutics by 334.3% during the 2nd quarter. Squarepoint Ops LLC now owns 181,740 shares of the company’s stock worth $1,730,000 after purchasing an additional 139,896 shares during the period. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Stock Up 4.3%

DYN stock opened at $15.23 on Thursday. Dyne Therapeutics, Inc. has a 52 week low of $6.36 and a 52 week high of $25.00. The company has a quick ratio of 13.47, a current ratio of 22.25 and a debt-to-equity ratio of 0.15. The firm has a 50-day simple moving average of $17.26 and a 200-day simple moving average of $17.04. The stock has a market capitalization of $2.51 billion, a P/E ratio of -4.30 and a beta of 1.34.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Monday, March 2nd. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.02). Equities analysts forecast that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

DYN has been the topic of a number of recent analyst reports. Evercore lowered their price target on shares of Dyne Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a report on Monday, December 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Wednesday, January 21st. Sanford C. Bernstein set a $23.00 target price on Dyne Therapeutics in a research report on Tuesday, December 9th. TD Cowen restated a “buy” rating on shares of Dyne Therapeutics in a research note on Monday, December 8th. Finally, Tudor Pickering set a $23.00 price target on Dyne Therapeutics in a report on Tuesday, December 9th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $37.00.

Dyne Therapeutics Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.